Artificial Intelligence
Bridgeline Announces Financial Results for the Fourth Quarter of Fiscal 2020
Recurring Revenue Increases by 20%
Positive Net Income, Operating Income and Adjusted EBITDA
WOBURN, Mass., Dec. 23, 2020 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), The Digital Engagement Company, today announced financial results for its fiscal fourth quarter ended September 30, 2020.
“In our fourth quarter, recurring revenue grew 20% and we delivered another quarter of strong profits,” said Ari Kahn, Bridgeline’s President and Chief Executive Officer. “In addition to our App Sales, which have hit a new high, we won multiple Enterprise Platform customers including a global franchise who committed to a multi-year agreement valued at more than $650,000 to power 200 websites with Bridgeline’s Unbound Franchise software.”
“Bridgeline continues to evaluate opportunities to acquire synergistic software companies that provide added value to our growing customer base and drive cross-selling opportunities,” continued Mr. Kahn. “The company evaluates several opportunities every month and is careful to select candidates who fulfill our strategic and financial goals.”
Fourth Quarter Summary:
- Total revenue, which is comprised of License and Services revenue, was consistent at $2.7 million for the quarters ended September 30, 2020 and 2019. License revenue grew by 20% and Services decreased by 31%.
- Subscription and perpetual licenses revenue, which is comprised of SaaS licenses, maintenance and hosting revenue and perpetual license revenue increased 20% to $2 million for the quarter ended September 30, 2020, from $1.7 million for the same period in 2019. As a percentage of total revenue, Subscription and perpetual license revenue increased 12% to 74% of total revenue for the quarter ended September 30, 2020, compared to 62% for the same period in 2019.
- Services revenue decreased $314,000 to $701,000 for the quarter ended September 30, 2020 as compared to $1 million for the same period in 2019. As a percentage of total revenue, Services revenue accounted for 26% of total revenue for the quarter ended September 30, 2020, compared to 38% for the same period in 2019.
- Gross profit increased 16% or $253,000 to $1.8 million for the quarter ended September 30, 2020 as compared to $1.6 million for the same period in 2019. Cost of revenue decreased 21% or $236,000 to $885,000 for the quarter ended September 30, 2020 compared to $1.1 million for the same period in 2019. Gross margin increased to 67% for the quarter ended September 30, 2020, compared to 58% for the same period in 2019. Subscription and perpetual licenses gross margin were 76% for three months ended September 30, 2020 as compared to 59% for the same period in 2019. Services gross margin were 43% for the three months ended September 30, 2020 as compared to 57% for the same period in 2019.
- Operating expenses decreased 46% or $1.4 million to $1.7 million for the quarter ended September 30, 2020 from $3.1 million for the same period in 2019. Included within the quarterly totals as of September 30, 2020 are the net benefits and overall efficiencies of the previously announced reduction of our U.S. and Canada operations by eliminating redundancies and combining certain responsibilities and functions. Included within the quarter ended September 2019 results are acquisition charges of $35,000 related to the acquisition of Stantive and Celebros, respectively.
- Operating income for the quarter ended September 30, 2020 is $164,000 as compared to an operating loss of $1.5 million for the same period in 2019.
- Net income applicable to common shareholders for the fiscal quarter ended September 30, 2020 is $1.1 million, compared to net income of $619,000 for the same period in 2019. Included within the net income for the three months ended September 30, 2020 was the non-cash loss of $50,000 attributable to the change in fair value of certain derivative warrant liabilities offset by the government grant income of $960,000 related to the forgiveness of the PPP loan. For the three months ended September 30, 2019, the net gain attributable to the change in fair value of certain derivative warrant liabilities was $2.2 million offset by the dividend on convertible preferred stock of $73,000, respectively.
Year to Date Summary:
- Total revenue, which is comprised of License and Services revenue, increased 10% to $11 million for the twelve months ended September 30, 2020, as compared to $10 million for the same period in 2019. License revenue grew by 29% and Services decreased by 17%.
- Subscription and perpetual licenses revenue, which is comprised of SaaS licenses, maintenance and hosting revenue and perpetual license revenue increased 29% to $7.5 million for the twelve months ended September 30, 2020, from $5.8 million for the same period in 2019. As a percentage of total revenue, Subscription and perpetual licenses revenue increased 10% to 69% of total revenue for the twelve months ended September 30, 2020, compared to 59% for the same period in 2019.
- Services revenue decreased $708,000 to $3.4 million for the twelve months ended September 30, 2020 as compared to $4.1 million for the same period in 2019. As a percentage of total revenue, Services revenue decreased 10% to 31% of total revenue for the twelve months ended September 30, 2020, compared to 41% for the same period in 2019.
- Gross profit increased 39% or $1.8 million to $6.4 million for the twelve months ended September 30, 2020 as compared to $4.6 million for the same period in 2019. Cost of revenue decreased 16% or $853,000 to $4.5 million for the twelve months ended September 30, 2020 compared to $5.4 million for the same period in 2019. Gross margin increased to 59% for the twelve months ended September 30, 2020, compared to 46% for the same period in 2019. Subscription and perpetual licenses gross margin were 64% for twelve months ended September 30, 2020 as compared to 44% for the same period in 2019. Services gross margin were 46% for the twelve months ended September 30, 2020 as compared to 50% for the same period in 2019.
- Operating expenses decreased 49% or $7.6 million to $8.1 million for the twelve months ended September 30, 2020 from $15.7 million for the same period in 2019. Included within the twelve month totals as of September 30, 2020 are restructuring charges of $366,000 which reflect the net benefits and overall efficiencies of the previously announced reduction of our U.S. and Canada operations by eliminating redundancies and combining certain responsibilities and functions. Included within the twelve months ended September 2019 results are acquisition charges of $1.1 million related to the acquisition of Stantive and Celebros and a goodwill impairment charge of $3.7 million respectively.
- Net loss applicable to common shareholders for the twelve months ended September 30, 2020 is $2.1 million, compared to $9.8 million for the same period in 2019. Included within the net loss for the twelve months ended September 30, 2020 is a non-cash gain of $1 million attributable to the change in fair value of certain derivative warrant liabilities, government grant income of $960,000 related to the forgiveness of the PPP loan and a deemed dividend expense on the amendment of convertible preferred stock of $2.3 million. For the twelve months ended September 30, 2019, the net gain attributable to the change in fair value of certain derivative warrant liabilities was $2.1 million offset by the dividend on convertible preferred stock of $315,000, respectively.
Financial Results
Fourth Quarter
Total revenue, which is comprised of License and Services revenue, was consistent at $2.7 million for the quarters ended September 30, 2020 and 2019. License revenue grew by 20% and Services decreased by 31%. Subscription and perpetual licenses revenue, which is comprised of SaaS licenses, maintenance and hosting revenue and perpetual license revenue increased 20% to $2 million for the quarter ended September 30, 2020, from $1.7 million for the same period in 2019. As a percentage of total revenue, Subscription and perpetual license revenue increased 12% to 74% of total revenue for the quarter ended September 30, 2020, compared to 62% for the same period in 2019. Services revenue decreased $314,000 to $701,000 for the quarter ended September 30, 2020 as compared to $1 million for the same period in 2019. As a percentage of total revenue, Services revenue accounted for 26% of total revenue for the quarter ended September 30, 2020, compared to 38% for the same period in 2019.
Gross profit increased 16% or $253,000 to $1.8 million for the quarter ended September 30, 2020 as compared to $1.6 million for the same period in 2019. Cost of revenue decreased 21% or $236,000 to $885,000 for the quarter ended September 30, 2020 compared to $1.1 million for the same period in 2019. Gross margin increased to 67% for the quarter ended September 30, 2020, compared to 58% for the same period in 2019. Subscription and perpetual licenses gross margin were 76% for three months ended September 30, 2020 as compared to 59% for the same period in 2019. Services gross margin were 43% for the three months ended September 30, 2020 as compared to 57% for the same period in 2019.
Operating expenses decreased 46% or $1.4 million to $1.7 million for the quarter ended September 30, 2020 from $3.1 million for the same period in 2019. Included within the quarterly totals as of September 30, 2020 are the net benefits and overall efficiencies of the previously announced reduction of our U.S. and Canada operations by eliminating redundancies and combining certain responsibilities and functions. Included within the quarter ended September 2019 results are acquisition charges of $35,000 related to the acquisition of Stantive and Celebros, respectively.
Operating income for the quarter ended September 30, 2020 is $164,000 as compared to an operating loss of $1.5 million for the same period in 2019.
Net income applicable to common shareholders for the fiscal quarter ended September 30, 2020 is $1.1 million, compared to net income of $619,000 for the same period in 2019. Included within the net income for the three months ended September 30, 2020 was the non-cash loss of $50,000 attributable to the change in fair value of certain derivative warrant liabilities offset by the government grant income of $960,000 related to the forgiveness of the PPP loan. For the three months ended September 30, 2019, the net gain attributable to the change in fair value of certain derivative warrant liabilities was $2.2 million offset by the dividend on convertible preferred stock of $73,000, respectively.
Adjusted EBITDA gain for the quarter ended September 30, 2020 is $455,000 or $0.10 per diluted share, compared to a loss of $1.2 million or $0.41 per diluted share for the same period in 2019.
Year to Date
Total revenue, which is comprised of License and Services revenue, increased 10% to $11 million for the twelve months ended September 30, 2020, as compared to $10 million for the same period in 2019. License revenue grew by 29% and Services decreased by 17%. Subscription and perpetual licenses revenue, which is comprised of SaaS licenses, maintenance and hosting revenue and perpetual license revenue increased 29% to $7.5 million for the twelve months ended September 30, 2020, from $5.8 million for the same period in 2019. As a percentage of total revenue, Subscription and perpetual licenses revenue increased 10% to 69% of total revenue for the twelve months ended September 30, 2020, compared to 59% for the same period in 2019. Services revenue decreased $708,000 to $3.4 million for the twelve months ended September 30, 2020 as compared to $4.1 million for the same period in 2019. As a percentage of total revenue, Services revenue decreased 10% to 31% of total revenue for the twelve months ended September 30, 2020, compared to 41% for the same period in 2019.
Gross profit increased 39% or $1.8 million to $6.4 million for the twelve months ended September 30, 2020 as compared to $4.6 million for the same period in 2019. Cost of revenue decreased 16% or $853,000 to $4.5 million for the twelve months ended September 30, 2020 compared to $5.4 million for the same period in 2019. Gross margin increased to 59% for the twelve months ended September 30, 2020, compared to 46% for the same period in 2019. Subscription and perpetual licenses gross margin were 64% for twelve months ended September 30, 2020 as compared to 44% for the same period in 2019. Services gross margin were 46% for the twelve months ended September 30, 2020 as compared to 50% for the same period in 2019.
Operating expenses decreased 49% or $7.6 million to $8.1 million for the twelve months ended September 30, 2020 from $15.7 million for the same period in 2019. Included within the twelve month totals as of September 30, 2020 are restructuring charges of $366,000 which reflect the net benefits and overall efficiencies of the previously announced reduction of our U.S. and Canada operations by eliminating redundancies and combining certain responsibilities and functions. Included within the twelve months ended September 2019 results are acquisition charges of $1.1 million related to the acquisition of Stantive and Celebros and a goodwill impairment charge of $3.7 million respectively.
Net loss applicable to common shareholders for the twelve months ended September 30, 2020 is $2.1 million, compared to $9.8 million for the same period in 2019. Included within the net loss for the twelve months ended September 30, 2020 is a non-cash gain of $1 million attributable to the change in fair value of certain derivative warrant liabilities, government grant income of $960,000 related to the forgiveness of the PPP loan and a deemed dividend expense on the amendment of convertible preferred stock of $2.3 million. For the twelve months ended September 30, 2019, the net gain attributable to the change in fair value of certain derivative warrant liabilities was $2.1 million offset by the dividend on convertible preferred stock of $315,000, respectively.
Adjusted EBITDA loss for the twelve months ended September 30, 2020 is $128,000 or $0.04 per diluted share, compared to $5.4 million or $4.49 per diluted share for the same period in 2019.
Conference Call:
Bridgeline Digital, Inc. will hold a conference call today, December 23, 2020 at 8:30 a.m. Eastern Time to discuss these results. The Company’s President and Chief Executive Officer, Ari Kahn and Chief Financial Officer, Mark G. Downey will host the call, followed by a question and answer period.
The details of the conference call and replay are as follows:
What: | Bridgeline Digital Fourth Quarter 2020 Earnings Call |
When: | Wednesday, December 23, 2020 |
Time: | 8:30 a.m. ET |
Live Call: | (877) 837-3910, domestic |
(973) 796-5077, international | |
Replay: | (855) 859-2056 |
(404) 537-3406 | |
Conference ID: | 5146118 |
Please call the conference telephone number 5 – 10 minutes prior to the start time. An operator will register your name and organization.
Non-GAAP Financial Measures
This press release contains the following non-GAAP financial measures: non-GAAP adjusted net income/(loss), non-GAAP adjusted earnings/(loss) per diluted share, Adjusted EBITDA and Adjusted EBITDA per diluted share.
Non-GAAP adjusted net income/(loss) and non-GAAP adjusted earnings/(loss) per diluted share are calculated as net income/(loss) or net income/(loss) per share on a diluted basis, excluding, where applicable, amortization of intangible assets, non-cash stock-based compensation, goodwill impairment charges, restructuring and acquisition-related costs, preferred stock dividends and any related tax effects.
Adjusted EBITDA and Adjusted EBITDA per diluted share are defined as earnings before interest, taxes, depreciation and amortization, non-cash stock-based compensation charges, goodwill impairment charges, restructuring and acquisition-related costs, changes in fair value of derivative liabilities and warrant expense, amortization of debt discounts, preferred stock dividends and any related tax effects. Bridgeline uses non-GAAP adjusted net income/(loss) and Adjusted EBITDA as supplemental measures of our performance that are not required by, or presented in accordance with, accounting principles generally accepted in the United States (“GAAP”).
Bridgeline’s management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, Bridgeline management presents non-GAAP financial measures in connection with GAAP results. Bridgeline urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which is included in this press release, and not to rely on any single financial measure to evaluate Bridgeline’s financial performance.
Our definitions of non-GAAP adjusted net income/(loss) and Adjusted EBITDA may differ from and therefore may not be comparable with similarly titled measures used by other companies, thereby limiting their usefulness as comparative measures. As a result of the limitations that non-GAAP adjusted net income and Adjusted EBITDA have as an analytical tool, investors should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP.
Safe Harbor for Forward-Looking Statements
Statement under the Private Securities Litigation Reform Act of 1995
All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, are based on our current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements appear in a number of places in this press release and include statements regarding the intent, belief or current expectations of Bridgeline Digital, Inc. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions, including, but not limited to, the impact of the COVID-19 pandemic and related public health measures that may affect our financial results; business operations and the business of our customers, suppliers and partners; our ability to retain and upgrade current customers, increasing our recurring revenue, our ability to attract new customers, our revenue growth rate; our history of net loss and our ability to achieve or maintain profitability, our liability for any unauthorized access to our data or our users’ content, including through privacy and data security breaches; any decline in demand for our platform or products; changes in the interoperability of our platform across devices, operating systems, and Fourth party applications that we do no control; competition in our markets; our ability to respond to rapid technological changes, extend our platform, develop new features or products, or gain market acceptance for such new features or products, particularly in light of potential disruptions to the productivity of our employees resulting from remote work; our ability to manage our growth or plan for future growth, and our acquisition of other businesses and the potential of such acquisitions to require significant management attention, disrupt our business, or dilute stockholder value; the volatility of the market price of our common stock, the ability to maintain our listing on the NASDAQ Capital Market, or our ability to maintain an effective system of internal controls as well as other risks described in our filings with the Securities and Exchange Commission. Any of such risks could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. Bridgeline Digital, Inc. assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release, except as required by applicable law.
About Bridgeline Digital
Bridgeline Digital, The Digital Engagement Company, helps customers maximize the performance of their omni-channel digital experience from websites and intranets to online stores and campaigns. Bridgeline’s Unbound platform is a Digital Experience Platform (DXP) that deeply integrates Web Content Management, eCommerce, Marketing Automation, Site Search, Authenticated Portals, Social Media Management, Translation, Locator Pages and Web Analytics to help the goal of assisting marketers to help organizations deliver digital experiences that attract, engage, nurture and convert their customers across all channels and streamline business operations. OrchestraCMS is the only content and digital experience platform built 100% native on Salesforce. OrchestraCMS helps Salesforce create digital experiences for their customers and partners; combining content with business data, processes and applications across multiply channels and device including Salesforce Communities, social media, portals, intranets, websites, applications and services. Celebros Search is a commerce oriented, site search product that provides for Natural Language Processing with artificial intelligence (AI) to present very relevant search results in seven languages. Headquartered in Woburn, MA., Bridgeline customers range from small- and medium-sized organizations to Fortune 1000 companies. To learn more, please visit www.bridgeline.com or call (800) 603-9936.
Contact:
Company Contact
Bridgeline Digital, Inc.
Mark G. Downey
Chief Financial Officer
(631) 203-6820
[email protected]
BRIDGELINE DIGITAL, INC. | |||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP RESULTS | |||||||||||||||||
(Dollars in thousands, except per share data) | |||||||||||||||||
Three Months Ended | Twelve Months Ended | ||||||||||||||||
September 30 | September 30 | ||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||
Reconciliation of GAAP net income/(loss) to | |||||||||||||||||
non-GAAP adjusted net income/(loss): | |||||||||||||||||
GAAP net income/(loss) | $ | 1,068 | $ | 619 | $ | (2,094 | ) | $ | (9,789 | ) | |||||||
Amortization of intangible assets | 213 | 234 | 891 | 544 | |||||||||||||
Stock-based compensation | 61 | 39 | 194 | 249 | |||||||||||||
Goodwill impairment charge | – | – | – | 3,732 | |||||||||||||
Restructuring and acquisition-related charges | (7 | ) | 35 | 366 | 1,053 | ||||||||||||
Convertible Preferred stock dividends | – | 73 | 2,420 | 315 | |||||||||||||
Non-GAAP adjusted net income/(loss) | $ | 1,335 | $ | 1,000 | $ | 1,777 | $ | (3,896 | ) | ||||||||
Reconciliation of GAAP net earnings/(loss) per diluted share to | |||||||||||||||||
non-GAAP adjusted net earnings/(loss) per diluted share: | |||||||||||||||||
GAAP net income/(loss) | $ | 0.24 | $ | 0.21 | $ | (0.59 | ) | $ | (8.16 | ) | |||||||
Amortization of intangible assets | 0.05 | 0.08 | 0.25 | 0.45 | |||||||||||||
Stock-based compensation | 0.01 | 0.01 | 0.05 | 0.21 | |||||||||||||
Goodwill impairment charge | – | – | – | 3.11 | |||||||||||||
Restructuring and acquisition-related charges | (0.00 | ) | 0.01 | 0.10 | 0.88 | ||||||||||||
Convertible Preferred stock dividends | – | 0.03 | 0.68 | 0.26 | |||||||||||||
Non-GAAP adjusted net earnings/(loss) per diluted share | $ | 0.29 | $ | 0.34 | $ | 0.50 | $ | (3.25 | ) | ||||||||
Reconciliation of GAAP net income/(loss) to Adjusted EBITDA: | |||||||||||||||||
GAAP net income/(loss) | $ | 1,068 | $ | 619 | $ | 326 | $ | (9,789 | ) | ||||||||
Provision for income tax | 2 | (3 | ) | 11 | 4 | ||||||||||||
Interest and other expense, net | 4 | (1 | ) | 7 | 303 | ||||||||||||
Government grant income | (960 | ) | – | (960 | ) | – | |||||||||||
Amortization of debt discount | – | – | – | 231 | |||||||||||||
Change in fair value of warrants | 50 | (2,212 | ) | (1,028 | ) | (13,404 | ) | ||||||||||
Warranty liability expense | – | – | – | 11,272 | |||||||||||||
Amortization of intangible assets | 213 | 234 | 891 | 544 | |||||||||||||
Depreciation | 21 | 16 | 61 | 66 | |||||||||||||
Goodwill impairment charge | – | – | – | 3,732 | |||||||||||||
Restructuring and acquisition-related charges | (7 | ) | 35 | 366 | 1,053 | ||||||||||||
Other amortization | 3 | 7 | 16 | 39 | |||||||||||||
Stock-based compensation | 61 | 39 | 194 | 249 | |||||||||||||
Convertible Preferred stock dividends | – | 73 | – | 315 | |||||||||||||
Adjusted EBITDA | $ | 455 | $ | (1,193 | ) | $ | (116 | ) | $ | (5,385 | ) | ||||||
Reconciliation of GAAP net earnings/(loss) per diluted share to | |||||||||||||||||
Adjusted EBITDA per diluted share: | |||||||||||||||||
GAAP net income/(loss) | $ | 0.24 | $ | 0.21 | $ | 0.09 | $ | (8.16 | ) | ||||||||
Provision for income tax | 0.00 | (0.00 | ) | 0.00 | 0.00 | ||||||||||||
Interest and other expense, net | 0.00 | (0.00 | ) | 0.00 | 0.25 | ||||||||||||
Government grant income | (0.21 | ) | – | (0.27 | ) | – | |||||||||||
Amortization of debt discount | – | – | – | 0.19 | |||||||||||||
Change in fair value of warrants | 0.01 | (0.76 | ) | (0.29 | ) | (11.18 | ) | ||||||||||
Warranty liability expense | – | – | – | 9.40 | |||||||||||||
Amortization of intangible assets | 0.05 | 0.08 | 0.25 | 0.45 | |||||||||||||
Depreciation | 0.00 | 0.01 | 0.02 | 0.06 | |||||||||||||
Goodwill impairment charge | – | – | – | 3.11 | |||||||||||||
Restructuring and acquisition-related charges | (0.00 | ) | 0.01 | 0.10 | 0.88 | ||||||||||||
Other amortization | 0.00 | 0.00 | 0.00 | 0.03 | |||||||||||||
Stock-based compensation | 0.01 | 0.01 | 0.05 | 0.21 | |||||||||||||
Convertible Preferred stock dividends | – | 0.03 | – | 0.26 | |||||||||||||
Adjusted EBITDA per diluted share | $ | 0.10 | $ | (0.41 | ) | $ | (0.03 | ) | $ | (4.49 | ) |
BRIDGELINE DIGITAL, INC. | |||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(Dollars in thousands, except share and per share data) | |||||||||||||||||
(Unaudited) | |||||||||||||||||
Three Months Ended | Twelve Months Ended | ||||||||||||||||
September 30, | September 30, | ||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||
Revenue: | |||||||||||||||||
Digital engagement services | $ | 701 | $ | 1,015 | $ | 3,409 | $ | 4,117 | |||||||||
Subscription and perpetual licenses | 2,004 | 1,673 | 7,498 | 5,835 | |||||||||||||
Total revenue | 2,705 | 2,688 | 10,907 | 9,952 | |||||||||||||
Cost of revenue: | |||||||||||||||||
Digital engagement services | 399 | 434 | 1,831 | 2,070 | |||||||||||||
Subscription and perpetual licenses | 486 | 687 | 2,676 | 3,290 | |||||||||||||
Total cost of revenue | 885 | 1,121 | 4,507 | 5,360 | |||||||||||||
Gross profit | 1,820 | 1,567 | 6,400 | 4,592 | |||||||||||||
Operating expenses: | |||||||||||||||||
Sales and marketing | 484 | 1,305 | 2,614 | 4,824 | |||||||||||||
General and administrative | 519 | 806 | 2,455 | 3,246 | |||||||||||||
Research and development | 423 | 686 | 1,641 | 2,185 | |||||||||||||
Depreciation and amortization | 237 | 259 | 968 | 620 | |||||||||||||
Goodwill impairment charge | – | – | – | 3,732 | |||||||||||||
Restructuring and acquisition-related | (7 | ) | 35 | 366 | 1,053 | ||||||||||||
Total operating expenses | 1,656 | 3,091 | 8,044 | 15,660 | |||||||||||||
Income (loss) from operations | 164 | (1,524 | ) | (1,644 | ) | (11,068 | ) | ||||||||||
Interest and other, net | (4 | ) | 1 | (7 | ) | (303 | ) | ||||||||||
Government grant income (Note 10) | 960 | – | 960 | – | |||||||||||||
Amortization of debt discount | – | – | – | (231 | ) | ||||||||||||
Warranty liability expense | – | – | – | (11,272 | ) | ||||||||||||
Change in fair value of warrant liabilities | (50 | ) | 2,212 | 1,028 | 13,404 | ||||||||||||
Income (loss) before income taxes | 1,070 | 689 | 337 | (9,470 | ) | ||||||||||||
Provision for income taxes | 2 | (3 | ) | 11 | 4 | ||||||||||||
Net income (loss) | $ | 1,068 | $ | 692 | $ | 326 | $ | (9,474 | ) | ||||||||
Dividends on convertible preferred stock | – | (73 | ) | (106 | ) | (315 | ) | ||||||||||
Deemed dividend on amendment of Series A convertible | |||||||||||||||||
preferred stock | – | – | (2,314 | ) | – | ||||||||||||
Net income (loss) applicable to common shareholders | $ | 1,068 | $ | 619 | $ | (2,094 | ) | $ | (9,789 | ) | |||||||
Net income/(loss) per share attributable to common shareholders: | |||||||||||||||||
Basic | $ | 0.24 | $ | 0.22 | $ | (0.59 | ) | $ | (8.16 | ) | |||||||
Diluted | $ | 0.24 | $ | 0.18 | $ | (0.59 | ) | $ | (8.16 | ) | |||||||
Number of weighted average shares outstanding: | |||||||||||||||||
Basic | 4,419,614 | 2,795,604 | 3,555,032 | 1,199,322 | |||||||||||||
Diluted | 4,526,700 | 2,915,438 | 3,555,032 | 1,199,322 |
BRIDGELINE DIGITAL, INC. | |||||||||
CONSOLIDATED BALANCE SHEETS | |||||||||
(Dollars in thousands, except share and per share data) | |||||||||
(Unaudited) | |||||||||
ASSETS | |||||||||
September 30 | September 30 | ||||||||
2020 | 2019 | ||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 861 | $ | 296 | |||||
Accounts receivable, net | 665 | 979 | |||||||
Prepaid expenses | 268 | 351 | |||||||
Other current assets | 111 | 49 | |||||||
Total current assets | 1,905 | 1,675 | |||||||
Property and equipment, net | 238 | 299 | |||||||
Operating lease assets | 294 | – | |||||||
Intangible assets, net | 2,617 | 3,509 | |||||||
Goodwill | 5,557 | 5,557 | |||||||
Other assets | 49 | 115 | |||||||
Total assets | $ | 10,660 | $ | 11,155 | |||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||
Current liabilities: | |||||||||
Current portion of operating lease liabilities | $ | 96 | $ | – | |||||
Accounts payable | 1,311 | 1,740 | |||||||
Accrued liabilities | 599 | 835 | |||||||
Paycheck Protection Program Liability (Note 10) | 88 | – | |||||||
Deferred revenue | 1,511 | 1,262 | |||||||
Total current liabilities | 3,605 | 3,837 | |||||||
Operating lease liabilities, net of current portion | 198 | – | |||||||
Warrant liabilities | 2,486 | 3,514 | |||||||
Other long-term liabilities | 15 | 8 | |||||||
Total liabilities | 6,304 | 7,359 | |||||||
Commitments and contingencies | |||||||||
Stockholders’ equity: | |||||||||
Preferred stock – $0.001 par value; 1,000,000 shares authorized; | |||||||||
Series C Convertible Preferred stock: | |||||||||
11,000 shares authorized; 350 shares at September 30, 2020 and 441 shares at September 30, 2019, issued and outstanding | – | – | |||||||
Series A Convertible Preferred stock: | |||||||||
264,000 shares authorized; no shares outstanding at September 30, 2020 and 262,310 shares at September 30, 2019, issued and outstanding | – | – | |||||||
Common stock – $0.001 par value; 50,000,000 shares authorized; | |||||||||
4,420,170 shares at September 30, 2020 and 2,798,475 shares at September 30, 2019, issued and outstanding | 4 | 3 | |||||||
Additional paid-in-capital | 78,316 | 75,620 | |||||||
Accumulated deficit | (73,583 | ) | (71,489 | ) | |||||
Accumulated other comprehensive loss | (381 | ) | (338 | ) | |||||
Total stockholders’ equity | 4,356 | 3,796 | |||||||
Total liabilities and stockholders’ equity | $ | 10,660 | $ | 11,155 |
Artificial Intelligence
Loyalty Juggernaut Receives US Patent for Innovative Technology Enabling Individualized Experiences at Scale
3rd Patent Award Adds to Growing IP Portfolio and Reinforces Commitment to Innovation
CHICAGO, May 20, 2024 /PRNewswire/ — CRMC Show – Loyalty Juggernaut, Inc. (LJI), the loyalty industry’s first cloud-native technology platform for Loyalty Programs, Loyalty Ecosystems, and Digital Marketing, today announced at CRMC that the United States Patent and Trademark Office has awarded a patent (#11978082) for LJI’s groundbreaking use of AI. This patented technology enables brands to deliver individualized offers to program members at scale.
“This transformative feature allows a single loyalty campaign to be personalized and tailored across an entire member base, effortlessly achieving what we call ‘mass individualization,’ which is the stated mission and #1 priority of loyalty programs globally,” said Shyam Shah, CEO and Co-Founder of Loyalty Juggernaut. “This patent marks a significant milestone for us and reinforces our vision of how loyalty programs engage customers by delivering experiences that are 1:1 personalized.”
This marks the third patent for LJI, making their GRAVTY® platform the only loyalty technology globally with patents for three essential capabilities required to future-proof today’s loyalty programs and ecosystems. The other two patents are for:
1.GRAVTY Visual Rules (GVR): The only patented “no-code” rules engine in the loyalty technology industry, empowering loyalty professionals by combining extreme sophistication with extraordinary simplicity (watch GVR in action here).
2. Multi-dimensional Behavior (1st party data) Tracking: This feature is particularly significant in today’s age of cookie-less consumers, as the reliance on high-quality first-party data grows in driving individualized customer experiences and maximizing the effectiveness of digital marketing and data-driven initiatives.
“Loyalty marketers are always looking for ways to engage customers 1:1 at scale. This innovation is groundbreaking in its use of AI to drive mass personalization, the holy grail of loyalty programs,” said Bill Hanifin, Chief Executive Officer, Wise Marketer Group.
Media Contact: [email protected]
About Loyalty Juggernaut
Headquartered in Silicon Valley, Loyalty Juggernaut, Inc. is the next-gen customer engagement and loyalty solutions enterprise helping brands transform their loyalty programs into data-led businesses to maximize customer value and compete at scale. LJI’s GRAVTY® platform powers over 40 loyalty ecosystems globally, involving 4,000+ participating brands across 12 industries including Retail, CPG, Hospitality, Airline, BFSI, Telco, and multi-brand diversified business conglomerates. Customers include Majid Al Futtaim, Liverpool, Global Hotel Alliance, Deutsche Telekom, Viva Aerobus.
#loyaltymarketing #loyaltyprograms #customerengagement #CX #individualization #personalization
Follow us on LinkedIn. More at www.lji.io
Logo: https://mma.prnewswire.com/media/2251954/4350951/Loyalty_Juggernaut_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/loyalty-juggernaut-receives-us-patent-for-innovative-technology-enabling-individualized-experiences-at-scale-302150520.html
Artificial Intelligence
Vantiva Powers New Vodafone Fiber Router and Wi-Fi 6 Mesh Extender to Enhance In-Home Broadband Experience
CPE leverages Vantiva’s Wi-Fi antenna expertise to connect more than 100 smart devices at ultra-high speeds
PARIS, May 20, 2024 /PRNewswire/ — Vantiva (Euronext Paris: VANTI), a global technology leader enabling Network Service Providers (NSPs) to connect consumers around the world, today announced that it has strengthened its longstanding partnership with Vodafone UK, the largest full fiber provider in the UK, with the introduction of the Wi-Fi 6 enabled Power Hub router and Super Wi-Fi 6 Booster. The customer premises equipment (CPE) leverages Vantiva’s Wi-Fi antenna expertise to offer intelligent Wi-Fi auto-optimization that automatically provides the fastest connectivity across all devices. The router and booster are designed to cost-effectively deliver a superior whole-home Wi-Fi experience to end-users with the ability to seamlessly connect more than 100 smart devices at speeds up to 910 Mbps.
“The introduction of the Power Hub router and Super Wi-Fi 6 Booster are the latest examples Vodafone UK’s continued leadership in bringing advanced connectivity solutions to its customers,” said Mercedes Pastor, Senior Vice-President of the Customer Unit, Eurasia. “This is a step forward in our long-time partnership delivering cutting edge solutions in this market. The outstanding Wi-Fi performance leverages all of Vantiva’s expertise from antenna design to unique testing environments to offer the best in-home wireless experience.”
Vodafone UK’s new Power Hub router is built for fiber-to-the-home network configuration and is easily adaptable for current and future in-home connectivity demands. The Super Wi-Fi 6 Booster works seamlessly with the Power Hub to give reliable coverage throughout the home and is compatible with both existing and previous versions of Vodafone gateways. The extender’s mesh Wi-Fi capability adapts the connectivity to give customers comprehensive Wi-Fi coverage.
As part of Vantiva’s commitment to developing eco-friendly products with low-carbon intensity, the device housing for these products was made from 95% recycled plastic. The packaging was designed using 85% recycled paper, printed with soy ink and uses no plastics.
Vantiva and Vodafone UK have been collaboratively bringing innovative solutions to market in multiple product platforms since 2018 and in fiber since 2022, when the two organizations introduced the first Wi-Fi 6E gateway in the UK, bringing high speed connectivity to homes across the country.
The Vodafone Power Hub Wi-Fi 6 router and Super Wi-Fi 6 Booster are the latest strategic milestones in Vantiva’s ongoing commitment to providing open and innovative technologies for NSPs and Pay TV operators. Vantiva’s goal is to bring seamless connectivity and premium entertainment experiences to consumers by creating best-in-class CPE and partnering with the most innovative companies in the connected home ecosystem.
Contact: Vantiva Press RelationsThatcher+Co. for [email protected]
PDF – https://mma.prnewswire.com/media/2416910/Vantiva_PDF.pdfLogo – https://mma.prnewswire.com/media/2411147/4715583/Vantiva_logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/vantiva-powers-new-vodafone-fiber-router-and-wi-fi-6-mesh-extender-to-enhance-in-home-broadband-experience-302150257.html
Artificial Intelligence
Life Science Equipment Market to be Worth $97.96 Billion by 2031 – Exclusive Report by Meticulous Research®
REDDING, Calif., May 20, 2024 /PRNewswire/ — According to a new market research report titled, ‘Life Science Equipment Market Size, Share, Forecast, & Trends Analysis By Technology (Spectroscopy, Microscopy, Chromatography (HPLC, GC, TLC), PCR, Immunoassay, Sequencing, Flow Cytometry, Microarray, Centrifuge) End User – Global Forecast to 2031,’ published by Meticulous Research®, the life science equipment market is projected to reach $97.96 billion by 2031, at a CAGR of 6.3% from 2024 to 2031.
Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=3937
Life sciences encompass a wide range of fields, including biology, biochemistry, genetics, pharmacology, and many more. Laboratory equipment plays a critical role in conducting experiments, collecting data, and analyzing samples to further scientific research and advance our understanding of living organisms and their underlying mechanisms. Equipment is also necessary for quality checks and validation of manufactured drugs and biologics in the life sciences industry. The growth of the life sciences industry is driving the adoption of life sciences and laboratory equipment.
The growth of this market is attributed to several factors, including increasing pharmaceutical and biotech R&D expenditures, government initiatives supporting life sciences R&D, the increasing prevalence of chronic and infectious diseases, and growth in initiatives to control environmental pollution. Additionally, the growth in genomics and proteomics, the increasing awareness and growing adoption of personalized medicines, increasing automation and digitalization in the life sciences industry, and the increasing focus on food safety and quality are expected to provide significant opportunities for players operating in the market.
The report offers a competitive landscape based on an extensive assessment of the leading players’ product portfolios and geographic presence and the key growth strategies adopted by them in the last three to four years. In recent years, the life science equipment market witnessed several product launches, product enhancements, product approvals, partnerships, agreements, & collaborations, acquisitions, and expansions.
The key players operating in the life science equipment market are Agilent Technologies, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Waters Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Siemens Healthineers AG (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), and QIAGEN N.V. (Netherlands).
Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=3937
Growing Awareness and Adoption of Personalized Medicine to Offer Opportunities for Players Operating in the Life Science Equipment Market
Personalized medicine, also known as precision medicine, is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup (also considering genetic changes resulting from a disease) and lifestyle habits. It is an emerging disease treatment and prevention approach that considers individual variability in genes, environment, and lifestyle.
Precision medicine can remove the need for guesswork, variable diagnostic ability, and treatment strategies based on generalized demographics. Moreover, precision medicine enables a more holistic view of an individual patient. Precision medicine for clinical workflows helps facilitate more predictive and preventive care by bringing targeted therapies. There has been an increase in the adoption of personalized medicine in recent years. For instance, according to the Personalized Medicine Coalition, the share of personalized medicine has increased steadily in the total drugs approved in the U.S. by the FDA, from 28% in 2015 to 35% in 2021. The increasing awareness and adoption of personalized medicine are driving the demand for specialized laboratory equipment and technologies that enable precise and accurate genetic and molecular analysis.
Personalized medicine heavily relies on genetic testing, sequencing, analysis of genetic, genomic, and proteomic information, and biomarker identification and validation. This necessitates the use of advanced laboratory equipment, such as DNA sequencers, gene sequencers, PCR machines, real-time PCR systems, next-generation sequencers, mass spectrometers, immunoassay analyzers, and chromatography systems, to accurately derive the necessary results.
The life science equipment market is segmented by Technology [Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzers, PCR, Sequencing, Flow Cytometry, Incubators, Microarray, Centrifuges, Electrophoresis, and Other Equipment], End User [Pharmaceutical and Biotechnology Industry, Academic & Research Institutes, Hospitals and Diagnostic Laboratories, Analytical Testing Laboratories, Agriculture and Food Industry, Forensic Laboratories, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets. (Note: Apart from primary segmentation, Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzer, PCR, Sequencing, Flow Cytometry, Microarray, Centrifuges, and Electrophoresis have further level segmentation).
Have Specific Research Needs? Request a Customized Report-https://www.meticulousresearch.com/request-customization/cp_id=3937
Among the technologies included in the report, in 2024, the spectroscopy segment is expected to account for the largest share of 22% of the life science equipment market. The spectroscopy segment is further sub-segmented into molecular spectroscopy, atomic spectroscopy, mass spectrometry, and software. In 2024, the molecular spectroscopy segment is expected to account for the largest share of the spectroscopy market. Molecular spectroscopy is used to determine the composition of a material in an unknown chemical composition. It is used in various applications across food & beverage, environmental screening, pharmaceutical, and biotech industries. Therefore, the wide range of applications of molecular spectroscopy coupled with the growth of the life sciences industry, especially the pharmaceutical and biotech sectors, contribute to the large market share of this segment.
Among the end users included in the report, in 2024, the pharmaceutical and biotechnology industry segment is expected to account for the largest share of 32% of the life science equipment market. The largest share is contributed by several factors, including the increased demand for new drugs and therapies leading to extensive research and development activities, the need for technologically advanced equipment in the pharmaceutical and biotech industries, the rise in funding and investments in the pharmaceutical and biotech industry, and increased healthcare expenditure.
Among the geographies included in the report, in 2024, North America is expected to account for the largest share of 41% of the life science equipment market. North America’s major market share is attributed to the presence of key players, its well-established life science industry, and substantial spending on R&D activities by pharmaceutical and biotech companies. The U.S. is home to global top-ranking pharmaceutical companies. Companies like Johnson & Johnson, Pfizer, AbbVie Inc., Merck, and Bristol Myers Squibb are headquartered in the U.S. These companies have high R&D expenditure at increasing at a high rate each year. For example, Johnson & Johnson spent USD 14.7 billion on research and development in 2021, with a 21% increase over 2020.
Brows In-depth Report- https://www.meticulousresearch.com/product/life-science-equipment-market-3937
Scope of the Report:
Life Science Equipment Market Assessment—by Technology
SpectroscopyMolecular SpectroscopyUV/Vis SpectroscopyNuclear Magnetic Resonance (NMR)Near-Infrared (NIR) SpectroscopyInfrared (IR) SpectroscopyRaman SpectroscopyPolarimeters and RefractometersFluorescence & Luminescence SpectroscopyOther Molecular Spectroscopy TechnologiesNote: Other molecular spectroscopy technologies segment includes Raman spectroscopy, ellipsometry, and color measurement
Mass SpectrometryQuadrupole LC/MSTime of Flight LC/MS (Q-TOF & LC-TOF)Gas Chromatography-Mass Spectrometry (GC/MS)Fourier Transform Mass Spectrometry (FT/MS)Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectroscopy (MALDI-TOF MS)Portable and In-Field Mass SpectroscopyTandem Mass Spectroscopy (MS/MS)Ion Trap Mass Spectroscopy (LC/MS)Atomic SpectroscopyAtomic Absorbance Spectroscopy (AAS)X-Ray Fluorescence (XRF) SpectroscopyX-Ray Diffraction (XRD) SpectroscopyOther Atomic Spectroscopy TechnologiesNote: Other atomic spectroscopy technologies segment includes inductively coupled plasma (ICP) spectroscopy, glow discharge spectroscopy, and arc/spark optical emission spectroscopy
Spectroscopy SoftwareMicroscopyElectron MicroscopyOptical MicroscopyScanning Probe MicroscopyOther MicroscopyMicroscopy SoftwareChromatographyHigh-Performance Liquid Chromatography (HPLC)Gas Chromatography (GC)Low Pressure Liquid Chromatography (LPLC)Flash ChromatographyThin Layer Chromatography (TLC)Ion ChromatographySupercritical Fluid Chromatography (SFC)Chromatography SoftwareLab AutomationAutomated WorkstationsRobotic SystemsAutomated Storage and Retrieval Systems (ASRS)Lab Automation SoftwareImmunoassay AnalyzersChemiluminescence ImmunoassayFluorescence ImmunoassayRadioimmunoassay (RIA)Colorimetric ImmunoassayOther Immunoassay AnalyzersImmunoassay SoftwarePCRRT-PCRConventional PCRDigital PCRPCR SoftwareSequencingFlow CytometryCell-Based Flow CytometersBead-Based Flow CytometersFlow Cytometry SoftwareIncubatorsMicroarrayDNA MicroarraysProtein MicroarrayTissue ArrayOther MicroarraysMicroarray SoftwareNote: Other microarrays segment includes glycan microarray, carbohydrate microarray, and chemical compounds microarrays
CentrifugesCentrifuges, by TypeDevicesMultipurpose CentrifugesMicrocentrifugesMini centrifugesUltracentrifugesOther CentrifugesCentrifuge AccessoriesCentrifuges, by ModelBenchtop CentrifugesFloor-standing CentrifugesCentrifuges, by ApplicationResearch ApplicationsGenomicsMicrobiologyCellomics ProteomicsClinical ApplicationsDiagnosticsBlood Processing and ScreeningOther ApplicationsElectrophoresisGel ElectrophoresisCapillary ElectrophoresisGel Documentation Systems and SoftwareOther EquipmentNote: Other equipment segment includes autoclaves, stirrers & shakers, mixers, baths, hot plates, ovens & furnaces, and balances
Life Science Equipment Market Assessment —by End User
Pharmaceutical and Biotechnology IndustryAcademic & Research InstitutesHospitals and Diagnostic LaboratoriesAnalytical Testing LaboratoriesAgriculture and Food IndustryForensic LaboratoriesOther End UsersNote: Other end users include blood banks and industries, such as cosmetics, chemicals, oil & gas, electronics & semiconductors, automotive, aerospace, ceramics, plastics, rubber, and paints & coatings
Life Science Equipment Market Assessment —by Geography
North AmericaU.S.CanadaEuropeGermanyU.K.FranceItalySpainSwitzerlandRest of Europe (RoE)Asia-Pacific (APAC)ChinaJapanIndiaSouth KoreaRest of APAC (RoAPAC)Latin AmericaBrazilMexicoRest of LATAM (RoLATAM)Middle East & AfricaSaudi ArabiaUAERest of Middle East & Africa (RoMEA)Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/26911858
Related Reports:
Genomics Market by Offering (Systems, Consumables, Software, Services), Technology (Sequencing, Microarray, PCR), Application (Diagnostics, Life Science Research), End User (Pharmaceutical Companies, Hospitals, Academic Institutes, CRO) – Global Forecast to 2030
NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) – Global Forecast to 2029
Liquid Handling Systems Market by Type (Automated, Electronic, Manual), Product (Pipette, Consumables, Burette, Software, Microplate), Application (Drug Discovery, Cancer & Genomics, Clinical), End User (Hospital, Diagnostic Lab) – Global Forecast to 2029
High-Performance Liquid Chromatography (HPLC) Market by Product (Instruments [Systems, Detectors], Consumables [Columns, Tubes], Accessories, Software), Application (Forensics, Diagnostics), End User (Research, Pharmaceuticals) – Global Forecast to 2030
Next Generation Sequencing Market by Type (Consumables, NGS Platform, Software), Sequencing Type (Whole Genome, Targeted), Technology (Sequencing by Synthesis, Sequencing by Ligation), Application (Clinical, Research), End User – Global Forecasts to 2030
Chromatography Reagents Market by Type (GC, LC, TLC), Product (Solvents, Buffers, Reagents), Separation (Adsorption, Partition, Affinity), Application (Pharma, Forensic, Environmental, Cosmeceuticals, Diagnostics, QC), End User – Global Forecast to 2030
Related Blogs:
Top 10 Companies in Life Science Equipment Market
Life Science Equipment: The Role of Various Technologies
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected] Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/348/life-science-equipment-market-2031
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
View original content:https://www.prnewswire.co.uk/news-releases/life-science-equipment-market-to-be-worth-97-96-billion-by-2031—exclusive-report-by-meticulous-research-302150104.html
-
Uncategorized6 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence4 days ago
Japan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized5 days ago
Google to roll out AI-generated summaries at top of search engine
-
Artificial Intelligence4 days ago
Strava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Uncategorized3 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence4 days ago
Data Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence3 days ago
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Uncategorized4 days ago
SoftBank looks at ‘softening’ angry customer calls with AI